RxDoctor Payments Data

Amber Anderson, NP

Acute Care · Cleveland, TNNPI 1184359309

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.1% of the total across 413 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,401, more than ten times the $122 reported in 2022. Among acute care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,982in general payments, 2019–2025

Across 413 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$1K
  • EMD Serono, Inc.$567
  • Pfizer$546
  • Argenx US, Inc.$523
  • Neurelis, Inc.$474
  • plus $5K from 38 others

What the payments were for

  • Travel & lodging$4315%
  • Food & beverage$8,45494%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,982 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$24,736
Medicare patients
169
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate12$13,600
Emgality PenGalcanezumab-Gnlm14$12,329
Levetiracetam58$4,216
Lacosamide16$2,975
Memantine Hcl105$2,212
Carbidopa-Levodopa ErCarbidopa/Levodopa34$2,125
Carbidopa-LevodopaCarbidopa/Levodopa58$1,958
Primidone46$1,292
Gabapentin59$1,046
Phenobarbital21$851
Duloxetine Hcl21$739
Donepezil Hcl43$397
Propranolol Hcl13$328
Topiramate19$286
Lamotrigine15$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$212$13,60012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.

Other acute care in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →